BioTuesdays

Tag - Naz Rahman

Cingulate Logo
Markets

Maxim starts Cingulate at buy; PT $3

Maxim Group launched coverage of Cingulate (NASDAQ:CING) with a “buy” rating and price target of $3. The stock closed at 69 cents on Nov. 21. Cingulate is a Phase 3-ready company developing multiple therapies for...

November 22, 2022
scPharmaceuticals Logo
Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022
Virpax Pharmaceuticals
Markets

Maxim starts Virpax at buy; PT $4

Maxim Group initiated coverage of Virpax Pharmaceuticals (NASDAQ:VRPX) with a “buy” rating and price target of $4. The stock closed at $1.55 on June 8. Virpax is a diversified pre-clinical stage company developing non...

June 9, 2022
180-Life-Sciences
Markets

Maxim cuts 180 Life Sciences to hold; withdraws PT

Maxim Group downgraded 180 Life Sciences (NASDAQ:ATNF) to “hold” from “buy” and withdrew its price target, citing a financing overhang. The stock closed at $1.31 on May 6. Several weeks ago, 180 announced the...

May 9, 2022
Markets

Maxim starts Processa Pharma at buy; PT $9

Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...

April 19, 2022
Agile Therapeutics
Markets

Maxim cuts Agile Therapeutics to hold; removes PT

Maxim Group downgraded Agile Therapeutics (NASDAQ:AGRX) to “hold” from “buy” and removed its price target, citing a financing overhang. The stock closed at 16 cents on April 7. Analyst Naz Rahman writes that Agile ended...

April 8, 2022
NexGel
Markets

Maxim starts NexGel at buy; PT $6

Maxim Group initiated coverage of NexGel (NASDAQ:NXGL) with a “buy” rating and a price target of $6. The stock closed at $1.81 on Feb. 24. NexGel manufactures, develops, and commercializes topical hydrogel-based...

February 25, 2022
NeuroSense Therapeutics
Markets

Maxim starts NeuroSense at buy; PT $7

Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...

January 7, 2022
Markets

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

January 7, 2022